...
首页> 外文期刊>British Journal of Cancer >Clinical significance of Caveolin-1, Caveolin-2 and HER2|[sol]|neu mRNA expression in human breast cancer
【24h】

Clinical significance of Caveolin-1, Caveolin-2 and HER2|[sol]|neu mRNA expression in human breast cancer

机译:乳腺癌中Caveolin-1,Caveolin-2和HER2 | [sol] | neu mRNA表达的临床意义

获取原文

摘要

Caveolin-1 and -2 (CAV1, CAV2) are closely linked genes localised to the fragile region of 7q31 (FRA7G), and loss of heterozygosity involving this region has been reported in breast cancer. Several studies have suggested that CAV1 is a negative regulator of HER2eu signal transduction in vitro. However, the clinical significance of CAV1 in breast cancer has not yet been clarified. We examined quantitatively the mRNA levels of CAV1, CAV2 and HER2eu in 162 cases of breast cancer using real-time PCR. Caveolin-1 and -2 protein expression was also examined by Western blotting and immunohistochemistry. We then evaluated for correlations between CAV1, CAV2 and HER2eu gene expression and clinicopathologic factors in the 162 breast cancer cases. Results showed higher HER2eu mRMA levels and lower CAV1 and CAV2 mRMA levels in breast cancer tissues than in corresponding normal tissues (PP=0.041), and negative oestrogen receptor status (P=0.021). There was also a significant association between low CAV2 mRNA level and negative progesterone receptor status (P=0.013), and between high HER2eu mRNA level and negative hormonal receptor status (ER, P=0.029, PgR, P=0.019). While there was no relationship between HER2eu and CAV1 mRNA levels, a significant association between CAV1 and CAV2 mRNA levels was observed (P<0.001). Our results indicated that CAV1 suppression correlated closely with that of CAV2 in breast cancer, that CAV1 level was inversely correlated with tumour size, and that CAV1 and CAV2 levels were correlated with hormonal receptor status. Therefore, CAV1 and CAV2 play an important role in tumour progression in breast cancer patients.
机译:Caveolin-1和-2(CAV1,CAV2)是紧密连接的基因,位于7q31的脆弱区域(FRA7G)中,据报道在乳腺癌中涉及该区域的杂合性丧失。多项研究表明,CAV1在体外是HER2 / neu信号转导的负调节剂。但是,CAV1在乳腺癌中的临床意义尚未阐明。我们使用实时PCR定量检查了162例乳腺癌患者中CAV1,CAV2和HER2 / neu的mRNA水平。还通过蛋白质印迹和免疫组织化学检查了Caveolin-1和-2蛋白的表达。然后,我们评估了162例乳腺癌病例中CAV1,CAV2和HER2 / neu基因表达与临床病理因素之间的相关性。结果显示,与相应的正常组织相比,乳腺癌组织中的HER2 / neu mRMA水平更高,CAV1和CAV2 mRMA水平更低(PP = 0.041),雌激素受体状态为阴性(P = 0.021)。在低CAV2 mRNA水平与阴性孕激素受体状态之间(P = 0.013),在高HER2 / neu mRNA水平与激素受体阴性状态之间也存在显着相关性(ER,P = 0.029,PgR,P = 0.019)。尽管HER2 / neu和CAV1 mRNA水平之间没有关系,但观察到CAV1和CAV2 mRNA水平之间存在显着关联(P <0.001)。我们的结果表明,乳腺癌中CAV1的抑制与CAV2的抑制密切相关,CAV1的水平与肿瘤大小成反比,并且CAV1和CAV2的水平与激素受体状态相关。因此,CAV1和CAV2在乳腺癌患者的肿瘤进展中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号